These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 31665091)
1. Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis. He Y; Zhang J; Shen G; Liu L; Zhao Q; Lu X; Yang H; Hong D BMC Pharmacol Toxicol; 2019 Oct; 20(1):62. PubMed ID: 31665091 [TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Gibson LJ; Dawson C; Lawrence DH; Bliss JM Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488 [TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Khosrow-Khavar F; Filion KB; Al-Qurashi S; Torabi N; Bouganim N; Suissa S; Azoulay L Ann Oncol; 2017 Mar; 28(3):487-496. PubMed ID: 27998966 [TBL] [Abstract][Full Text] [Related]
4. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data. Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789 [TBL] [Abstract][Full Text] [Related]
5. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022 [TBL] [Abstract][Full Text] [Related]
6. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808 [TBL] [Abstract][Full Text] [Related]
7. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis. Yu Q; Xu Y; Yu E; Zheng Z J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740 [TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety profiles of aromatase inhibitors : a comparative review. Nabholtz JM; Gligorov J Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964 [TBL] [Abstract][Full Text] [Related]
10. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cuppone F; Bria E; Verma S; Pritchard KI; Gandhi S; Carlini P; Milella M; Nisticò C; Terzoli E; Cognetti F; Giannarelli D Cancer; 2008 Jan; 112(2):260-7. PubMed ID: 18041059 [TBL] [Abstract][Full Text] [Related]
11. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Mouridsen HT Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085 [TBL] [Abstract][Full Text] [Related]
12. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. Goldvaser H; Barnes TA; Šeruga B; Cescon DW; Ocaña A; Ribnikar D; Amir E J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922781 [TBL] [Abstract][Full Text] [Related]
13. Acupuncture for Arthralgia Induced by Aromatase Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis. Liu X; Lu J; Wang G; Chen X; Xv H; Huang J; Xue M; Tang J Integr Cancer Ther; 2021; 20():1534735420980811. PubMed ID: 33586504 [TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study. Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496 [TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter. Gandhi S; Verma S Breast Cancer Res Treat; 2007 Nov; 106(1):1-9. PubMed ID: 17211535 [TBL] [Abstract][Full Text] [Related]
17. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542 [TBL] [Abstract][Full Text] [Related]
18. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Perez EA Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211 [TBL] [Abstract][Full Text] [Related]
19. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]